{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:20:15Z","timestamp":1779337215830,"version":"3.51.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01EY034477"],"award-info":[{"award-number":["R01EY034477"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13346-025-02029-x","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T20:18:58Z","timestamp":1766521138000},"page":"1249-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic model for drug delivery by Ozurdex"],"prefix":"10.1007","volume":"16","author":[{"given":"Kumara","family":"Bommanahalli Nagaraju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishee","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Kompella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1920-2900","authenticated-orcid":false,"given":"Anuj","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2029_CR1","unstructured":"Sapatnekar T, Chandra G Ophthalmic Drugs Market by Indication, Type, Dosage Form, Technology, Distribution, and Therapeutic Class - Global Opportunity Analysis and Industry Forecast, 2017-2023. Allied Market Research. (2017). https:\/\/www.alliedmarketresearch.com\/ophthalmic-drugs-market"},{"key":"2029_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u2013e116.","journal-title":"Lancet Glob Health"},{"key":"2029_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17925\/EOR.2014.08.01.i","volume":"8","author":"S Wolf","year":"2014","unstructured":"Wolf S. Diabetic macular oedema and the importance of vascular endothelial growth factor therapies in its treatment. Eur Ophthalmic Rev. 2014;8:53\u201360.","journal-title":"Eur Ophthalmic Rev"},{"key":"2029_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/02713680590968628","volume":"30","author":"H Zhu","year":"2005","unstructured":"Zhu H, Chauhan A. A mathematical model for tear drainage through the canaliculi. Curr Eye Res. 2005;30:621\u201330.","journal-title":"Curr Eye Res"},{"key":"2029_CR5","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.drudis.2019.05.035","volume":"24","author":"FJ Cabrera","year":"2019","unstructured":"Cabrera FJ, Wang DC, Reddy K, Acharya G, Shin CS. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today. 2019;24:1679\u201384.","journal-title":"Drug Discov Today"},{"key":"2029_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/pharmaceutics15041094","volume":"15","author":"KY Wu","year":"2023","unstructured":"Wu KY, Joly-Chevrier M, Akbar D, Tran SD. Overcoming treatment challenges in posterior segment diseases with biodegradable nano-based drug delivery systems. Pharmaceutics. 2023;15:1094.","journal-title":"Pharmaceutics"},{"key":"2029_CR7","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s11095-009-9930-2","volume":"26","author":"K Hosoya","year":"2009","unstructured":"Hosoya K, Tachikawa M. Inner blood-retinal barrier transporters: role of retinal drug delivery. Pharm Res. 2009;26:2055\u201365.","journal-title":"Pharm Res"},{"key":"2029_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0002-9394(03)00483-5","volume":"136","author":"DM Moshfeghi","year":"2003","unstructured":"Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791\u20136.","journal-title":"Am J Ophthalmol"},{"key":"2029_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/archopht.122.3.336","volume":"122","author":"MC Gillies","year":"2004","unstructured":"Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336\u201340.","journal-title":"Arch Ophthalmol"},{"key":"2029_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5693\/djo.01.2014.07.001","volume":"21","author":"RY Karabag","year":"2015","unstructured":"Karabag RY, Parlak M, Cetin G, Yaman A, Saatci AO. Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports. Digit J Ophthalmol. 2015;21:8\u201310.","journal-title":"Digit J Ophthalmol"},{"key":"2029_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"K Falavarjani","year":"2013","unstructured":"Falavarjani K, Nguyen Q. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye Lond. 2013;27:787\u201394.","journal-title":"Eye Lond"},{"key":"2029_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1211\/jpp.59.5.0002","volume":"59","author":"T Loftsson","year":"2007","unstructured":"Loftsson T, Hreinsd\u00f3ttir D, Stef\u00e1nsson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol. 2007;59:629\u201335.","journal-title":"J Pharm Pharmacol"},{"key":"2029_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jconrel.2005.09.049","volume":"110","author":"E Eljarrat-Binstock","year":"2006","unstructured":"Eljarrat-Binstock E, Domb AI. Iontophoresis: a non-invasive ocular drug delivery. J Control Release. 2006;110:479\u201389.","journal-title":"J Control Release"},{"key":"2029_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coph.2017.07.007","volume":"36","author":"K Moffatt","year":"2017","unstructured":"Moffatt K, Wang Y, Singh T, Donnelly R. Microneedles for enhanced transdermal and intraocular drug delivery. Curr Opin Pharmacol. 2017;36:14\u201321.","journal-title":"Curr Opin Pharmacol"},{"key":"2029_CR15","first-page":"183","volume":"1","author":"N Shoeibi","year":"2014","unstructured":"Shoeibi N, Mahdizadeh M, Shafiee M. Iontophoresis in ophthalmology: a review of the literature. Rev Clin Med. 2014;1:183\u20138.","journal-title":"Rev Clin Med"},{"key":"2029_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.iop.0000225749.83440.2a","volume":"22","author":"P Custer","year":"2006","unstructured":"Custer P, McCaffery S. Complications of sclera-covered enucleation implants. Ophthalmic Plast Reconstr Surg. 2006;22:269\u201373.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2029_CR17","first-page":"27","volume":"29","author":"N Astbury","year":"2016","unstructured":"Astbury N, Nyamai LA. Detecting and managing complications in cataract patients. Community Eye Health. 2016;29:27\u20139.","journal-title":"Community Eye Health"},{"key":"2029_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","volume":"14","author":"R Thakur Singh","year":"2017","unstructured":"Thakur Singh R, Tekko I, McAvoy K, McMillan H, Jones D, Donnelly R. Minimally invasive microneedles for ocular drug delivery. Expert Opin Drug Deliv. 2017;14:525\u201337.","journal-title":"Expert Opin Drug Deliv"},{"key":"2029_CR19","first-page":"394","volume":"12","author":"K Tahara","year":"2017","unstructured":"Tahara K, Karasawa K, Onodera R, Takeuchi H. Feasibility of drug delivery to the eye\u2019s posterior segment by topical instillation of PLGA nanoparticles. Asian J Pharm Sci. 2017;12:394\u20139.","journal-title":"Asian J Pharm Sci"},{"key":"2029_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/0975-7406.116792","volume":"5","author":"H Gupta","year":"2013","unstructured":"Gupta H. Updates on drug bioavailability and delivery to posterior segment of eye. J Pharm Bioallied Sci. 2013;5:173\u20134.","journal-title":"J Pharm Bioallied Sci"},{"key":"2029_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijpharm.2017.04.010","volume":"531","author":"T Loftsson","year":"2017","unstructured":"Loftsson T, Stefanasson E. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye. Int J Pharm. 2017;531:412\u201323.","journal-title":"Int J Pharm"},{"key":"2029_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8567912","volume":"2018","author":"P Lau","year":"2018","unstructured":"Lau P, Jenkins K, Layton C. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;2018:8567912.","journal-title":"J Ophthalmol"},{"key":"2029_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133968","volume":"10","author":"A Ferreira","year":"2015","unstructured":"Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F. Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA. PLoS One. 2015;10:e0133968.","journal-title":"PLoS One"},{"key":"2029_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40266-012-0015-2","volume":"29","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Aflibercept for intravitreal injection in neovascular age-related macular degeneration. Drugs Aging. 2012;29:839\u201346.","journal-title":"Drugs Aging"},{"key":"2029_CR25","first-page":"2485","volume":"50","author":"M Siegel","year":"2009","unstructured":"Siegel M, Hughes B, Juzych M, Alexander M, Goyal A, Wolfe S, et al. Effect of intravitreal bevacizumab (Avastin) on intraocular pressure in patients with and without glaucoma. Invest Ophthalmol Vis Sci. 2009;50:2485.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1755-3768.2010.02064.x","volume":"89","author":"C Meyer","year":"2011","unstructured":"Meyer C, Michels S, Rodrigues E, Hager A, Mennel S, Schmidt J, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol. 2011;89:70\u20135.","journal-title":"Acta Ophthalmol"},{"key":"2029_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/IAE.0b013e31821067c4","volume":"31","author":"AA Moshfeghi","year":"2011","unstructured":"Moshfeghi AA, Rosenfeld PJ, Flynn Jr HW, Schwartz SG, Davis JL, Murray TG, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31:662\u20138.","journal-title":"Retina"},{"key":"2029_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","volume":"152","author":"S Day","year":"2011","unstructured":"Day S, Acquah K, Mruthyunjaya P, Grossman D, Lee P, Sloan F. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266\u201372.","journal-title":"Am J Ophthalmol"},{"key":"2029_CR29","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1097\/IAE.0b013e3181dc04da","volume":"30","author":"D Chong","year":"2010","unstructured":"Chong D, Anand R, Williams P, Qureshi J, Callanan D. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30:1432\u201340.","journal-title":"Retina"},{"key":"2029_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM Del Amo","year":"2017","unstructured":"Del Amo EM, Rimpel\u00e4 AK, Heikkinen E, Kari OK, Ramsay E, Lajunen T, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134\u201385.","journal-title":"Prog Retin Eye Res"},{"key":"2029_CR31","doi-asserted-by":"publisher","first-page":"37676","DOI":"10.1038\/srep37676","volume":"6","author":"J Tian","year":"2016","unstructured":"Tian J, Liu J, Liu X, Xiao Y, Tang L. Intravitreal infusion: a novel approach for intraocular drug delivery. Sci Rep. 2016;6:37676.","journal-title":"Sci Rep"},{"key":"2029_CR32","first-page":"191","volume":"4","author":"K Falavarjani","year":"2009","unstructured":"Falavarjani K. Implantable posterior segment drug delivery devices: novel alternatives to currently available treatments. J Ophthalmic Vis Res. 2009;4:191\u20133.","journal-title":"J Ophthalmic Vis Res"},{"key":"2029_CR33","first-page":"317","volume":"6","author":"N Haghjou","year":"2011","unstructured":"Haghjou N, Soheilian M, Abdekhodaie M. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6:317\u201329.","journal-title":"J Ophthalmic Vis Res"},{"key":"2029_CR34","unstructured":"Lopez A, Albini T. Therapeutic options for uveitis. Retina Today. 2017;October issue. https:\/\/retinatoday.com\/articles\/2017-oct\/therapeutic-options-for-uveitis. Accessed 26 Mar 2015."},{"key":"2029_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drudis.2007.11.002","volume":"13","author":"EM Del Amo","year":"2008","unstructured":"Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13:135\u201343.","journal-title":"Drug Discov Today"},{"key":"2029_CR36","unstructured":"Bausch and Lomb. Long term continuous control: treatment of chronic non-infectious uveitis-RETISERT\u00ae. https:\/\/pi.bausch.com\/globalassets\/pdf\/PackageInserts\/Pharma\/retisert-prescribing-information.pdf"},{"key":"2029_CR37","unstructured":"Issue: care of patients with chronic noninfectious posterior uveitis. Retinal Physician. 2011;March. https:\/\/retinalphysician.com\/issues\/2011\/march\/implantation-and-removal-procedures\/#:~:text=Retinal%20Physician%20March%201%2C%202011,be%20visible%20through%20the%20pupil."},{"key":"2029_CR38","volume":"2014","author":"M Cabera","year":"2014","unstructured":"Cabera M, Yeh S, Albini T. Sustained-release corticosteroid options. J Ophthalmol. 2014;2014:164692.","journal-title":"J Ophthalmol"},{"key":"2029_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.joco.2018.10.007","volume":"31","author":"A Kumar","year":"2018","unstructured":"Kumar A, Ambiya V, Kapoor G, Arora A. Wandering Ozurdex in eyes with scleral fixated intraocular lens and its management: a report of two cases. J Curr Ophthalmol. 2018;31:345\u20138.","journal-title":"J Curr Ophthalmol"},{"key":"2029_CR40","first-page":"107","volume":"4","author":"C Lowder","year":"2011","unstructured":"Lowder C, Hollander D. Review of the drug-infused eye implant-Ozurdex\u00ae (Dexamethasone intravitreal implant). US Ophthalmic Rev. 2011;4:107\u201312.","journal-title":"US Ophthalmic Rev"},{"key":"2029_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4137\/OED.S38028","volume":"8","author":"F Pacella","year":"2016","unstructured":"Pacella F, Ferraresi AF, Turchetti P. Intravitreal injection of Ozurdex\u00ae implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis. 2016;8:11\u20136.","journal-title":"Ophthalmol Eye Dis"},{"key":"2029_CR42","unstructured":"Kiss S. Sustained-release corticosteroid delivery systems. Retina Today. 2010;May\/June:44\u201346."},{"key":"2029_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0025-5564(94)90018-3","volume":"123","author":"KJ Tojo","year":"1994","unstructured":"Tojo KJ, Ohtori A. Pharmacokinetic model of intravitreal drug injection. Math Biosci. 1994;123:59\u201375.","journal-title":"Math Biosci"},{"key":"2029_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0169-409X(01)00187-9","volume":"52","author":"K Tojo","year":"2001","unstructured":"Tojo K, Isowaki A. Pharmacokinetic model for in vivo\/in vitro correlation of intravitreal drug delivery. Adv Drug Deliv Rev. 2001;52:17\u201324.","journal-title":"Adv Drug Deliv Rev"},{"key":"2029_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.65.11.28","volume":"65","author":"A Sadeghi","year":"2024","unstructured":"Sadeghi A, Subrizi A, del Amo EM, Urtti A. Mathematical models of ocular drug delivery. Invest Ophthalmol Vis Sci. 2024;65:28.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02946-1","volume":"37","author":"M Lamminsalo","year":"2020","unstructured":"Lamminsalo M, Karvinen T, Subrizi A, Urtti A, Ranta VP. Extended pharmacokinetic model of the intravitreal injections of macromolecules in rabbits. Part 2: parameter estimation based on concentration dynamics in the vitreous, retina, and aqueous humor. Pharm Res. 2020;37:226.","journal-title":"Pharm Res"},{"key":"2029_CR47","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","volume":"14","author":"LA Hutton-Smith","year":"2017","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Gadkar K, Mazer NA. Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model. Mol Pharm. 2017;14:2690\u20136.","journal-title":"Mol Pharm"},{"key":"2029_CR48","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.addr.2006.07.025","volume":"58","author":"VP Ranta","year":"2006","unstructured":"Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006;58:1164\u201381.","journal-title":"Adv Drug Deliv Rev"},{"key":"2029_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.65.12.21","volume":"65","author":"P Lamirande","year":"2024","unstructured":"Lamirande P, Gaffney EA, Gertz M, Maini PK, Crawshaw JR, Caruso A. A first-passage model of intravitreal drug delivery and residence time-influence of ocular geometry, individual variability, and injection location. Invest Ophthalmol Vis Sci. 2024;65:21.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR50","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.xphs.2024.12.005","volume":"114","author":"JM Chowdhury","year":"2025","unstructured":"Chowdhury JM, Chacin Ruiz EA, Ohr MP, Swindle-Reilly KE, Ford Versypt AN. Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes. J Pharm Sci. 2025;114:1164\u201374.","journal-title":"J Pharm Sci"},{"key":"2029_CR51","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s11095-010-0163-1","volume":"27","author":"PJ Missel","year":"2010","unstructured":"Missel PJ, Horner M, Muralikrishnan R. Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model. Pharm Res. 2010;27:1530\u201346.","journal-title":"Pharm Res"},{"key":"2029_CR52","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","volume":"29","author":"PJ Missel","year":"2012","unstructured":"Missel PJ. Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes. Pharm Res. 2012;29:3251\u201372.","journal-title":"Pharm Res"},{"key":"2029_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF02648045","volume":"25","author":"S Friedrich","year":"1997","unstructured":"Friedrich S, Cheng YL, Saville B. Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. Ann Biomed Eng. 1997;25:303\u201314.","journal-title":"Ann Biomed Eng"},{"key":"2029_CR54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jconrel.2005.03.010","volume":"105","author":"J Park","year":"2005","unstructured":"Park J, Bungay PM, Lutz RJ, Augsburger JJ, Millard RW, Sinha Roy A, et al. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release. 2005;105:279\u201395.","journal-title":"J Control Release"},{"key":"2029_CR55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s11095-010-0356-7","volume":"28","author":"RK Balachandran","year":"2011","unstructured":"Balachandran RK, Barocas VH. Contribution of saccadic motion to intravitreal drug transport: theoretical analysis. Pharm Res. 2011;28:1049\u201364.","journal-title":"Pharm Res"},{"key":"2029_CR56","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s11095-008-9691-3","volume":"25","author":"RK Balachandran","year":"2008","unstructured":"Balachandran RK, Barocas VH. Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow. Pharm Res. 2008;25:2685\u201396.","journal-title":"Pharm Res"},{"key":"2029_CR57","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s11095-023-03560-7","volume":"40","author":"N Toffoletto","year":"2023","unstructured":"Toffoletto N, Saramago B, Serro AP, Chauhan A. A physiology-based mathematical model to understand drug delivery from contact lenses to the back of the eye. Pharm Res. 2023;40:1939\u201351.","journal-title":"Pharm Res"},{"key":"2029_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108486","volume":"205","author":"H Fuchs","year":"2021","unstructured":"Fuchs H, Chen LZ, Low S, Yu H. Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys-evidence for half-life extension by albumin. Exp Eye Res. 2021;205:108486.","journal-title":"Exp Eye Res"},{"key":"2029_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000063123","volume":"171","author":"A Barathi","year":"2002","unstructured":"Barathi A, Thu MK, Beuerman RW. Dimensional growth of the rabbit eye. Cells Tissues Organs. 2002;171:276\u201385.","journal-title":"Cells Tissues Organs"},{"key":"2029_CR60","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1167\/iovs.05-0647","volume":"46","author":"BT Gabelt","year":"2005","unstructured":"Gabelt BT, Okka M, Dean TR, Kaufman PL. Aqueous humor dynamics in monkeys after topical R-DOI. Invest Ophthalmol Vis Sci. 2005;46:4691\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/eye.1997.43","volume":"11","author":"SF Nilsson","year":"1997","unstructured":"Nilsson SF. The uveoscleral outflow routes. Eye Lond. 1997;11:149\u201354.","journal-title":"Eye Lond"},{"key":"2029_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0014-4835(73)90099-7","volume":"16","author":"TM Wilson","year":"1973","unstructured":"Wilson TM, Strang R, Wallace J, Horton PW, Johnson NF. The measurement of the choroidal blood flow in the rabbit using 85-krypton. Exp Eye Res. 1973;16:421\u20135.","journal-title":"Exp Eye Res"},{"key":"2029_CR63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/02713688809031801","volume":"7","author":"MA Watsky","year":"1988","unstructured":"Watsky MA, Jablonski MM, Edelhauser HF. Comparison of conjunctival and corneal surface areas in rabbit and human. Curr Eye Res. 1988;7:483\u20136.","journal-title":"Curr Eye Res"},{"key":"2029_CR64","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/pharmaceutics13050655","volume":"13","author":"HM Kim","year":"2021","unstructured":"Kim HM, Han H, Hong HK, Park JH, Park KH, Kim H, et al. Permeability of the retina and RPE-choroid-sclera to three ophthalmic drugs and the associated factors. Pharmaceutics. 2021;13:655.","journal-title":"Pharmaceutics"},{"key":"2029_CR65","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/j.xphs.2017.04.061","volume":"106","author":"E Ramsay","year":"2017","unstructured":"Ramsay E, Ruponen M, Picardat T, Tengvall U, Tuomainen M, Auriola S, et al. Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of in silico model. J Pharm Sci. 2017;106:2463\u201371.","journal-title":"J Pharm Sci"},{"key":"2029_CR66","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1124\/dmd.110.037408","volume":"39","author":"A Thakur","year":"2011","unstructured":"Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos. 2011;39:771\u201381.","journal-title":"Drug Metab Dispos"},{"key":"2029_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/jop.2014.0100","volume":"31","author":"FE Kane","year":"2015","unstructured":"Kane FE, Green KE. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. J Ocul Pharmacol Ther. 2015;31:11\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2029_CR68","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/0042-6989(94)00320-L","volume":"35","author":"P Lapuerta","year":"1995","unstructured":"Lapuerta P, Schein SJ. A four-surface schematic eye of macaque monkey obtained by an optical method. Vision Res. 1995;35:2245\u201354.","journal-title":"Vision Res"},{"key":"2029_CR69","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1167\/iovs.06-1376","volume":"48","author":"F Manns","year":"2007","unstructured":"Manns F, Parel JM, Denham D, Billotte C, Ziebarth N, Borja D, et al. Optomechanical response of human and monkey lenses in a lens stretcher. Invest Ophthalmol Vis Sci. 2007;48:3260\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR70","first-page":"443","volume":"43","author":"RH Trivedi","year":"2002","unstructured":"Trivedi RH, Werner L, Apple DJ, Pandey SK, Izak AM. Dimensions of rabbit eyes with relevance for intraocular lens research. Invest Ophthalmol Vis Sci. 2002;43:443.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR71","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/archophthalmol.2011.39","volume":"129","author":"A Thakur","year":"2011","unstructured":"Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129:914\u201320.","journal-title":"Arch Ophthalmol"},{"key":"2029_CR72","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1021\/acs.molpharmaceut.9b00585","volume":"16","author":"EM Heikkinen","year":"2019","unstructured":"Heikkinen EM, Auriola S, Ranta VP, Demarais NJ, Grey AC, del Amo EM, et al. Distribution of small molecular weight drugs into the porcine lens: studies on imaging mass spectrometry, partition coefficients, and implications in ocular pharmacokinetics. Mol Pharm. 2019;16:3968\u201376.","journal-title":"Mol Pharm"},{"key":"2029_CR73","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1089\/jop.2014.0082","volume":"30","author":"R Bhagat","year":"2014","unstructured":"Bhagat R, Zhang J, Farooq S, Li XY. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes. J Ocul Pharmacol Ther. 2014;30:854\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2029_CR74","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1167\/iovs.10-6387","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52:4605\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejpb.2023.04.003","volume":"187","author":"MA Costello","year":"2023","unstructured":"Costello MA, Liu J, Chen B, Wang Y, Qin B, Xu X, et al. Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants. Eur J Pharm Biopharm. 2023;187:46\u201356.","journal-title":"Eur J Pharm Biopharm"},{"key":"2029_CR76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2029_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122625","volume":"634","author":"MA Costello","year":"2023","unstructured":"Costello MA, Liu J, Wang Y, Qin B, Xu X, Li Q, et al. Reverse engineering the Ozurdex dexamethasone intravitreal implant. Int J Pharm. 2023;634:122625.","journal-title":"Int J Pharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-02029-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-02029-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-02029-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:04:10Z","timestamp":1772553850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-02029-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-02029-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}